ClinicalTrialsFinder
RecruitingNot ApplicableNCT04662970

Optimization of Cardiac Resynchronization Therapy by Non-Invasive Imaging of Cardiac Electrophysiology

Optimization of Cardiac Resynchronization Therapy by Non-Invasive Imaging of Cardiac Electrophysiology: A Pilot Study

Sponsor

Medical University Innsbruck

Enrollment

25 participants

Start Date

Jan 1, 2020

Study Type

INTERVENTIONAL

Conditions

Heart Failure

Summary

The principal aim is to analyze total left and right ventricular activation time in different CRT device programming algorithms (SyncAV) measured by non-invasive electrophysiology

Eligibility

Min Age: 18 Years

Inclusion Criteria3

  • patients after successful implantation of a CRT-D or CRT-P device in whom a cardiac magnetic resonance examination is possible and the device is equipped with the SyncAV® programming software
  • left bundle branch block before CRT implantation
  • PQ interval ≤ 250 ms before implantation

Exclusion Criteria6

  • high-grade AV block
  • any contraindication concerning a safe CMR performance including claustrophobia
  • terminal heart failure (NYHA IV) or cardiac decompensation
  • life expectancy \< 1 year
  • women with child-bearing potential, pregnancy
  • drug abusus

Interventions

DEVICEDevice programming

Non-invasive electrophysiology with 65 ECG leads will be performed in 16 different device programming

Locations(1)

Medical University Innsbruck

Innsbruck, Tyrol, Austria

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04662970

Related Trials

Mind Your Heart-II

NCT054311921 location

A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart

NCT06935370641 locations

A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure

NCT06424288652 locations

Timing of Coronary Angiography in NSTEMI Complicated by Acute HF

NCT0700216420 locations

ML Score Prediction of Cardiotoxicity in Cancer Patients Receiving Anthracycline Chemotherapy or HER2-Targeted Therapies

NCT071917301 location